Read by QxMD icon Read

Thrombosis in cancer

shared collection
13 papers 100 to 500 followers
A A Khorana, S Noble, A Y Y Lee, G Soff, G Meyer, C O'Connell, M Carrier
No abstract text is available yet for this article.
September 2018: Journal of Thrombosis and Haemostasis: JTH
Juan J López-Núñez, Javier Trujillo-Santos, Manuel Monreal
Venous thromboembolism (VTE) is a frequent complication and a major cause of death in patients with cancer. Large population-based studies and disease registry surveys have revealed that around 20% of patients with VTE have active cancer. In these patients, VTE is not only associated with shortened survival, but it also has an impact on quality of life because of chronic, residual symptoms and anxiety from fear of recurrence. However, there is also evidence that bleeding to death is a major complication for some cancer patients receiving anticoagulants to manage their VTE...
September 23, 2018: Journal of Thrombosis and Haemostasis: JTH
B T Samuelson Bannow, A Lee, A A Khorana, J I Zwicker, S Noble, C Ay, M Carrier
No abstract text is available yet for this article.
June 2018: Journal of Thrombosis and Haemostasis: JTH
Agnes Y Y Lee
The optimal duration of anticoagulation in patients with cancer-associated venous thromboembolism (VTE) is unknown. Without well-designed studies evaluating the efficacy, safety and cost-effectiveness of continuing anticoagulant therapy beyond the acute treatment period of 3 to 6 months, evidence-based recommendations are lacking. Consensus guidelines generally suggest continuing anticoagulation in patients with active cancer or receiving cancer treatment, with periodic reassessment of the risks and benefits...
December 6, 2017: Blood
Ang Li, David A Garcia, Gary H Lyman, Marc Carrier
INTRODUCTION: It is unclear if direct oral anticoagulants (DOACs) are effective and safe alternatives to low-molecular-weight heparin (LMWHs) for the treatment of cancer-associated venous thromboembolism (VTE). We aim to synthesize existing literature that compared DOACs versus LMWHs in this high-risk population. MATERIALS AND METHODS: We conducted a systematic review using EMBASE, MEDLINE and CENTRAL for all observational studies and randomized controlled trials (RCTs) (PROSPERO: CRD42017080898)...
March 2, 2018: Thrombosis Research
Majed S Al Yami, Hisham A Badreldin, Abdelhameed H Mohammed, Ahmed M Elmubark, Mohammed Y Alzahrani, Abdulmajeed M Alshehri
Low molecular weight heparins (LMWHs) are considered the standard of care for the treatment of venous thromboembolism (VTE) associated with cancer. We conducted a meta-analysis to evaluate the safety and efficacy of direct oral anticoagulants (DOACs) in patients with cancer. We systematically searched Medline for potential randomized-control clinical trials (RCTs) and post-hoc analyses. For each study, data on recurrent VTE, major or clinically relevant non-major bleeding (CRNMB), and major bleeding (MB) were extracted...
August 2018: Journal of Thrombosis and Thrombolysis
Maria Cristina Vedovati, Michela Giustozzi, Gianluca Bonitta, Giancarlo Agnelli, Cecilia Becattini
BACKGROUND: Low-molecular-weight heparins (LMWHs) are the recommended treatment for cancer-associated venous thrombosis (CAT). Recent evidences suggest a role for direct-acting oral anticoagulants (DOACs) in this clinical setting. METHODS: To evaluate the efficacy and safety of different anticoagulants we performed a network meta-analysis of RCTs including patients with CAT treated with LMWHs, vitamin K antagonists (VKAs) or DOACs. MEDLINE and EMBASE were searched up to February 2018...
October 2018: Thrombosis Research
Ryma Ihaddadene, Grégoire Le Gal, Aurélien Delluc, Marc Carrier
INTRODUCTION: Patients with cancer-associated thrombosis are at a high risk of developing recurrent events despite anticoagulant therapy. Escalation of the dose of low molecular weight heparin (LMWH) has been suggested as a potential treatment option to manage these patients. We sought to confirm the benefit and risk of this management strategy in patients with recurrent cancer-associated thrombosis. MATERIAL AND METHODS: A retrospective cohort study of consecutive cancer outpatients seen for management of a symptomatic recurrent cancer-associated thrombosis while on anticoagulation was undertaken...
July 2014: Thrombosis Research
Ingrid Pabinger, Johannes Thaler, Cihan Ay
Cancer patients are at increased risk of deep vein thrombosis and pulmonary embolism. The incidence among different groups of cancer patients varies considerably depending on clinical factors, the most important being tumor entity and stage. Biomarkers have been specifically investigated for their capacity of predicting venous thromboembolism (VTE) during the course of disease. Parameters of blood count analysis (elevated leukocyte and platelet count and decreased hemoglobin) have turned out to be useful in risk prediction...
September 19, 2013: Blood
Jasmijn F Timp, Sigrid K Braekkan, Henri H Versteeg, Suzanne C Cannegieter
Cancer-associated venous thrombosis is a common condition, although the reported incidence varies widely between studies depending on patient population, start and duration of follow-up, and the method of detecting and reporting thrombotic events. Furthermore, as cancer is a heterogeneous disease, the risk of venous thrombosis depends on cancer types and stages, treatment measures, and patient-related factors. In general, cancer patients with venous thrombosis do not fare well and have an increased mortality compared with cancer patients without...
September 5, 2013: Blood
Jim Murray, Elizabeth Precious, Raza Alikhan
Central venous catheters are commonly used in haematology departments for the administration of chemotherapy, blood products and parenteral nutrition in patients with haematological malignancy. Thrombosis is a recognized complication of such devices especially in oncology patients. Catheter-related thrombi (CRT) may lead to pulmonary embolism and infection, as well as catheter failure and potential delays in treatment. The vast majority of CRT are asymptomatic, thus a high index of suspicion is required in making the diagnosis...
September 2013: British Journal of Haematology
Agnes Y Y Lee, Erica A Peterson
Therapeutic options for the management of venous thromboembolism (VTE) in patients with cancer remain very limited. Although low-molecular-weight heparin monotherapy has been identified as a simple and efficacious regimen compared with an initial parenteral anticoagulant followed by long-term therapy with a vitamin K antagonist, many clinical questions remain unanswered. These include optimal duration of anticoagulant therapy, treatment of recurrent VTE, and the treatment of patients with concurrent bleeding or those with a high risk of bleeding...
October 3, 2013: Blood
M Carrier, A A Khorana, J I Zwicker, S Noble, A Y Y Lee
No abstract text is available yet for this article.
September 2013: Journal of Thrombosis and Haemostasis: JTH
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"